Press Releases

April 30, 2018

BOSTON , April 30, 2018 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq:ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that Ron Cooper, President and Chief Executive Officer, is scheduled to present at the Deutsche Bank 43 rd

March 15, 2018
— Phase 3 PFIC trial of IBAT inhibitor A4250 planned to initiate in spring 2018 — — Elobixibat approved in Japan , becoming the first IBAT inhibitor approved in the world — — ~$200 million current cash balance expected to be sufficient to fund operations into 2021 — — Management to host conference